As 2024 wraps up, end-of-year research highlights—from AI-driven disease detection to expanded diagnoses and novel trial milestones—are shaping …
As 2024 wraps up, end-of-year research highlights—from AI-driven disease detection to expanded diagnoses and novel trial milestones—are shaping …
With generative AI powering personalized insights, Dexcom’s new Stelo CGM enters the market as the first FDA-cleared over-the-counter …
From decentralized designs to ethical reform, the NIH Pragmatic Trials Collaboratory closes 2024 with a blueprint for smarter, …
With its first-in-class mechanism and monthly dosing, Depemokimab sets a new benchmark in biologic treatment for high-burden asthma …
NIH-backed research reveals that a simple skin test may revolutionize early diagnosis of Parkinson’s and related neurodegenerative disorders.
The bispecific antibody earns full approval after demonstrating durable responses in heavily pre-treated patients.
Landmark Series A round positions Australian biotech at the forefront of neurodegenerative disease innovation.
The CGM giant and smart ring innovator join forces to integrate biosensor data and reshape personal health tracking.
New molecular imaging techniques show promise in improving cancer surgery precision and outcomes.
New CMS rules signal a turning point for AI-powered cardiac diagnostics, paving the way for broader clinical adoption …
Already a subscriber? Log in